KemPharm Inc. (NASDAQ:KMPH) shares fell 5.5% during trading on Wednesday . The company traded as low as $3.85 and last traded at $3.92, with a volume of 86,150 shares changing hands. The stock had previously closed at $4.15.

A number of brokerages have recently commented on KMPH. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of KemPharm in a research note on Saturday, May 14th. Royal Bank Of Canada reiterated a “buy” rating on shares of KemPharm in a research note on Sunday, May 8th. Zacks Investment Research cut KemPharm from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research note on Saturday, May 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.80.

The company’s market capitalization is $57.40 million. The stock has a 50-day moving average of $5.49 and a 200 day moving average of $12.88.

KemPharm (NASDAQ:KMPH) last released its quarterly earnings data on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.26. On average, equities research analysts anticipate that KemPharm Inc. will post ($2.79) earnings per share for the current year.

An institutional investor recently raised its position in KemPharm stock. EAM Investors LLC raised its position in shares of KemPharm Inc. (NASDAQ:KMPH) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,253 shares of the specialty pharmaceutical company’s stock after buying an additional 240 shares during the period. EAM Investors LLC owned about 0.42% of KemPharm worth $1,216,000 as of its most recent filing with the SEC.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. It uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs by chemically attaching one or more molecules, referred to as ligands, to the parent drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.